高能量除会增加心肌活化后心肌功能障碍的严重程度
Circulation
|July 15, 1997
概括
放电冲击的能量水平显著影响心脏骤停后的存活率和心脏功能. 在老鼠中,低能量的电动除与更好的结果和心肌功能障碍的减少有关.
科学领域:
- 心脏病学 心脏病学
- 紧急医疗 紧急医疗
- 身体生理学 身体生理学
背景情况:
- 心脏骤停复苏的结果受到缺血和再流伤害的影响.
- 以前的研究表明,除能量与心肌功能障碍之间存在联系.
研究的目的:
- 为了研究电动除能量和心肌复苏后心肌功能之间的关系.
- 为了确定除能量是否影响心脏骤停后的存活率.
主要方法:
- 在老鼠中诱导了心室动,随后进行了胸部压缩和通风.
- 使用不同的能量水平 (2,10,20朱尔) 进行了外部除.
- 血液动力学参数和存活率被监测了240分钟的复苏后.
主要成果:
- 所有的动物都在除后幸存下来,但心肌功能受损.
- 较低的除能量 (2 焦耳) 导致显著更好的心脏指数和左心室压力动态.
- 存活时间与除能量相反相关:20J (5小时),10J (15小时),2J (>24小时).
结论:
- 复苏后心肌功能障碍的严重程度与电动除过程中提供的能量直接相关.
- 优化除能量可能会改善心脏骤停后的结果.
相关概念视频
01:29Disturbances in Heart Rhythm
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
01:30Cardiac Action Potential
Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:23Cardiopulmonary Resuscitation III: AED Use
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...